Status:
COMPLETED
Syndecan-1 a Surrogate Marker for IBD
Lead Sponsor:
Meir Medical Center
Conditions:
Inflammatory Bowel Diseases
Eligibility:
All Genders
18-60 years
Brief Summary
Syndecan-1 is a protein on the surface intestinal cells. previous studies proved low levels of mucosal syndecan-1 levels on the surface of intestinal cells is patients with acute and chronic inflammat...
Detailed Description
One of the main hypothesis for the etiology of Inflammatory bowel disease (IBD) is an inappropriate and ongoing activation of the mucosal immune system in response to the presence of normal luminal fl...
Eligibility Criteria
Inclusion
- informed consent
- no other concurrent inflammatory disease
- formal diagnosis of inflammatory bowel disease i.e Crohn's disease, Ulcerative colitis
Exclusion
- pregnancy
- fever at time of sample taking
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01430039
Start Date
October 1 2011
End Date
April 1 2015
Last Update
April 8 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meir Medical Center
Kfar Saba, Israel